Development of a Cre-Inducible Rabl6a Transgenic Mouse Model That Enhances Sarcoma Growth In Vivo
Ellen M Voigt1,2,3, Alexandra L Isaacson4, Mariah R Leidinger4
1Cancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.
Cancers
|July 28, 2026
Summary
RABL6A drives malignant peripheral nerve sheath tumor (MPNST) progression by increasing angiogenesis, not proliferation. This study establishes a new mouse model for MPNST research.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas lacking effective treatments.
- RABL6A, an oncogenic GTPase, is crucial for MPNST cell survival and its expression correlates with poor patient outcomes.
- Elevated RABL6A is observed in human MPNSTs compared to benign precursors.
Purpose of the Study:
- To investigate the in vivo role of RABL6A in MPNST development and progression.
- To develop and validate a transgenic mouse model for studying RABL6A-driven MPNSTs.
Main Methods:
- Generated Cre-inducible Rabl6a transgenic mice (Rabl6a-tg).
- Created double transgenic DhhCre; Rabl6a-tg mice for Schwann cell-specific RABL6A expression.
- Induced de novo MPNSTs in mice via CRISPR editing of Nf1, Ink4a, and Arf genes.
Main Results:
- Transgenic Rabl6a expression accelerated MPNST progression in vivo.
- Accelerated progression was linked to increased tumor angiogenesis, not proliferation.
- Observed rhabdomyoblastic (RMB) features in some MPNSTs, a phenotype associated with malignant Triton tumors.
Conclusions:
- Rabl6a acts as a functional driver of MPNST progression.
- Rabl6a-tg mice provide a valuable model for studying RABL6A's role in MPNSTs and other cancers.
- Rabl6a promotes MPNST progression through enhanced angiogenesis and potentially contributes to rhabdomyoblastic differentiation.
